The Institute was proposing that TA228 should be moved to the ‘static guidance list’ and be incorporated into the ongoing clinical guideline for the diagnosis and management of myeloma.

After consideration of all of the comments received during the review consultation, the technology appraisals programme has decided to proceed with this proposal.

Consequently, TA228 will be moved to the ‘static guidance list’ and the recommendations will be incorporated into the forthcoming clinical guideline for the diagnosis and management of myeloma, which is scheduled to be published in January 2016.

April 2015

Attachments